[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340787-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340787-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deciphering-antigen-processing-machinery-apm-as-one-of-the-determinants-for-responsiveness-of-affected-patients-towards-anticancer-immunotherapy","Deciphering Antigen Processing Machinery (APM) as One of the Determinants for Responsiveness of Affected Patients towards Anticancer Immunotherapy","","Anticancer immunotherapy aims to reinvigorate immune cytotoxicity and sustain tumor protection through memory subsets. Immune checkpoint inhibitors (ICIs), including FDA-approved use for non-small lung cancer, depend on antigen processing machinery (APM), which processes antigens for loading onto HLA molecules to drive immune clearance. Impaired APM components are frequently present in tumors, reshaping HLA expression and the peptide repertoire presented to T lymphocytes. Proper peptide-HLA complexes are therefore required for effective T cell priming and differentiation, including ICI-related mechanisms and broader antitumor immunity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deciphering-antigen-processing-machinery-apm-as-one-of-the-determinants-for-responsiveness-of-affected-patients-towards-anticancer-immunotherapy/340787/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deciphering-antigen-processing-machinery-apm-as-one-of-the-determinants-for-responsiveness-of-affected-patients-towards-anticancer-immunotherapy/340787.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does APM relate to responsiveness to immune checkpoint inhibitors?","Question",{"text":63,"@type":64},"APM processes antigens before they are loaded onto HLA molecules. This peptide-HLA presentation enables the immune clearance mechanisms that support ICI effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are APM impairments commonly observed in tumors?",{"text":68,"@type":64},"Tumor progression requires immune recognition evasion. Alterations in APM can downregulate HLA molecules and change the antigenic peptide repertoire presented to T lymphocytes.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the role of peptide-HLA complexes in anticancer immunity?",{"text":72,"@type":64},"Processed antigen (peptide)-HLA complexes are critical for successful T cell priming and differentiation into cytotoxic effector cells. Without an appropriate complex, the presentation feature required for tumor eradication is compromised.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340787,1790463351,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","REVIEW  \nEditorial Process: Submission:07/31/2024 Acceptance:12/23/2024  \nDeciphering Antigen Processing Machinery (APM) as Oneof the Determinants for Responsiveness of Affected Patients towards Anticancer Immunotherapy  \nIka Nurlaila*  \nAbstract  \nImmunotherapy is one of the rising stars in the field of anticancer regiments. Aimed at reinvigorating immune cytotoxicity, this platform is capable of bulking up memory subsets by which protection against tumors is served. The most commonly applied immunotherapy is immune checkpoint inhibitor (ICIs) which received FDA approval for nonsmall lung cancer (NSLC) in 2014. The response toward ICI is closely related to the antigen processing machinery (APM) within which antigens are processed prior to loading onto the human leukocyte antigen (HLA) to induce cascade mechanisms for immune clearance. APM allows immune cell infiltration thus strengthens immunogenicity. Impaired components ofthe APM are frequently found in tumors because tumor progression requires tumor cells to acquire immune recognition evasion. Alterations in tumors’ APM result in downregulation of HLA molecules and transformation of antigenic peptide repertoire presented to the T lymphocytes. Interactions of processed antigens (peptide)-HLA complex are critical for successful T cell priming and differentiation into cytotoxic effector cells. The interaction underlies not only ICI-related mechanism but also anticancer immunity in general where T cell subset can induce antitumor recognition only if a proper peptide-HLA complex is present. This feature, unfortunately, is missing in tumors. This Review highlights presentation of tumor-specific antigens to T cells in HLA-restricted manner which leads to their eradication. This is a pivotal, but in most cases this is overlooked, which might add some volume to the off-target and less functional of anticancer immunotherapy.  \nKeywords: antigen processing machinery (APM)-immune checkpoint inhibitors (ICIs)-immunogenicity  \nAsian Pac J Cancer Prev, 25 (12), 4457-4464  \nIntroduction  \nImmunotherapy has been one of the rising stars in the field of anticancer regiments for the last four decades [1] . This strategy is designed to reinvigorate immune cytotoxicity [2] and bulk up memory cells which are expected to provide long-term protection against tumors [3]. There are diverse platforms in immunotherapy ranging from dendritic cell (DC) therapy, either that applied as adoptive DCs or DC-based vaccine [4, 5], to immune checkpoint inhibitor (ICI) with the later mentioned received FDA approval for non-small lung cancer (NSLC) patients treatment in 2014 [6-8] and become the most commonly implemented among all anticancer immunotherapy platforms hitherto. ICI exhibits efficacy in tumor rejection and improves patients’ survival rate by blocking the receptor-ligand interactions of immune checkpoint molecules. The response toward ICI is closely related to the antigen processing machinery (APM) within which antigens are processed prior to loading onto the human leukocyte antigen (HLA) to induce cascade mechanisms for immune clearance [9]. TheAPM  \ncomprises a network of cellular components essential for processing and presenting antigens to T cells by antigenpresenting cells (APCs) . When there are impairments intheAPM, the immune system’s capacity to detect and react to cancer cells can be hindered, facilitating the emergence of tumors that can evade immune surveillance [10]. Key elements ofthe APM include proteasomes, which breakdown proteins into peptides; transporter associated with antigen processing (TAP), which carries peptides from the cytoplasm to the endoplasmic reticulum (ER); and human leukocyte antigen (HLA) molecules that display these peptides on APC surfaces for T cells to recognize [10]. Increasing evidence indicates that APM defects can play a significant role in tumorigenesis. Mutations in genes responsible for proteasomes or TAP can impair peptide generation for presentation on","cbCaipl8KDovL7cr","https://ap.wps.com/l/cbCaipl8KDovL7cr","pdf",407260,"English","# Introduction\n# APM gene signature","[{\"question\":\"How does APM relate to responsiveness to immune checkpoint inhibitors?\",\"answer\":\"APM processes antigens before they are loaded onto HLA molecules. This peptide-HLA presentation enables the immune clearance mechanisms that support ICI effectiveness.\"},{\"question\":\"Why are APM impairments commonly observed in tumors?\",\"answer\":\"Tumor progression requires immune recognition evasion. Alterations in APM can downregulate HLA molecules and change the antigenic peptide repertoire presented to T lymphocytes.\"},{\"question\":\"What is the role of peptide-HLA complexes in anticancer immunity?\",\"answer\":\"Processed antigen (peptide)-HLA complexes are critical for successful T cell priming and differentiation into cytotoxic effector cells. Without an appropriate complex, the presentation feature required for tumor eradication is compromised.\"}]","Deciphering Antigen Processing Machinery (APM) as One of the Determinants for Responsiveness of Affected Patients towards Anticancer Immunotherapy | PDF",1790038904,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/baa20a2f7fa74341da9a3182fa62dc79.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1497c37a03999de5e32a490c3eb253b.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4691e17f2444a912249434bc4849758.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a54d59188f4c2fcf604d38d981b3f0a.webp",980,1385]